Update on the appropriate use of meropenem for the treatment of serious bacterial infections

Clinical Infectious Diseases

Volumn 47, Issue SUPPL.1, 2008, Pages

  Kollef, Marin H ^a  

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAMASE; CEPHALOSPORIN DERIVATIVE; MEROPENEM;

ABDOMINAL INFECTION; ANTIMICROBIAL THERAPY; BACTERIAL INFECTION; BACTERIAL MENINGITIS; BACTERICIDAL ACTIVITY; DECISION MAKING; DRUG EFFICACY; EDITORIAL; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MORBIDITY; MORTALITY; PRIORITY JOURNAL; SKIN INFECTION; SURVIVAL;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; HUMANS; THIENAMYCINS;

EID: 51549084303     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/590060     Document Type: Editorial

References (25)

1. Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis 2000; 31(Suppl 4):S131-8.
2. Ramphal R. Importance of adequate initial antimicrobial therapy. Chemotherapy 2005; 51:171-6.
3. Harbarth S, Nobre V, Pittet D. Does antibiotic selection impact patient outcome? Clin Infect Dis 2007; 44:87-93.
4. NNIS System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. Am J Infect Control 2003; 31:481-98.
5. Jones RN. Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: a five-year summary from the SENTRY Antimicrobial Surveillance Program (1997-2001). Semin Respir Crit Care Med 2003; 24:121-34.
6. Bruinsma N, Kristinsson KG, Bronzwaer S, et al. Trends of penicillin and erythromycin resistance among invasive Streptococcus pneumoniae in Europe. J Antimicrob Chemother 2004; 54:1045-50.
7. Peralta G, Sánchez MB, Garrido JC, et al. Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteraemia. J Antimicrob Chemother 2007; 60:855-63.
8. Schwaber MJ, Navon-Venezia S, Kaye KS, Ben-Ami R, Schwatrz D, Carmeli Y. Clinical and economic impact of bacteremia with extended-spectrum-β- lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2006; 50:1257-62.
9. Tumbarello M, Sanguinetti M, Montuori E, et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-β- lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother 2007; 51:1987-94.
10. Schramm GE, Johnson JA, Doherty JA, Micek ST, Kollef MH. Methicillin-resistant Staphylococcus aureus sterile-site infection: the importance of appropriate initial antimicrobial treatment. Crit Care Med 2006; 34:2069-74.
11. Lautenbach E, Metlay JP, Bilker WB, Edelstein PH, Fishman NO. Association between fluoroquinolone resistance and mortality in Escherichia coli and Klebsiella pneumoniae infections: the role of inadequate empirical antimicrobial therapy. Clin Infect Dis 2005; 41:923-9.
12. Kollef MH. Appropriate empirical antibacterial therapy for nosocomial infections: getting it right the first time. Drugs 2003; 63:2157-68.
13. Kollef MH, Morrow LE, Niederman MS, et al. Clinical characteristics and treatment patterns among patients with ventilator-associated pneumonia. Chest 2006; 129:1210-8.
14. Shlaes DM, Gerding DN, John JF Jr, et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: Guidelines for the Prevention of Antimicrobial Resistance in Hospitals. Clin Infect Dis 1997; 25:584-99.
15. Bradley JS, Garau J, Lode H, Rolston KVI, Wilson SE, Quinn JP. Carbapenems in clinical practice: a guide to their use in serious infection. Int J Antimicrob Agents 1999; 11:93-100.
16. Lodise TP, Lomaestro BM, Drusano GL, Society of Infectious Diseases Pharmacists. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2006; 26:1320-32.
17. MERREM I.V. (meropenem for injection) [package insert]. Wilmington, DE: Astra-Zeneca Pharmaceuticals, 2007.
18. Mohr JF 3rd. Update on the efficacy and tolerability of meropenem in serious bacterial infections. Clin Infect Dis 2008; 47(Suppl 1):S41-51 (in this supplement).
19. Nicolau DP. Pharmacokinetic and pharmacodynamic properties of meropenem. Clin Infect Dis 2008; 47(Suppl 1):S32-40 (in this supplement).
20. Ayalew K, Nambiar S, Yasinskaya Y, Jantausch BA. Carbapenems in pediatrics. Ther Drug Monit 2003; 25:593-9.
21. Zhanel GG, Wiebe R, Dilay L, et al. Comparative review of the carbapenems. Drugs 2007; 67:1027-52.
22. Kollef MH. Broad-spectrum antimicrobials and the treatment of serious bacterial infections: getting it right up front. Clin Infect Dis 2008; 47(Suppl 1):S3-13 (in this supplement).
23. Paterson DL. Impact of antibiotic resistance in gram-negative bacilli on empirical and definitive antibiotic therapy. Clin Infect Dis 2008; 47(Suppl 1):S14-20 (in this supplement).
24. Masterton R. The importance and future of antimicrobial surveillance studies. Clin Infect Dis 2008; 47(Suppl 1):S21-31 (in this supplement).
25. Brink AJ, Feldman C, Grolman DC, et al. Appropriate use of the carbapenems. S Afr Med J 2004; 94:857-61.